Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirusc (CMV) Infection Using Bayesian Prediction.
Phase of Trial: Phase IV
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Ganciclovir (Primary) ; Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Pharmacokinetics
- 26 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 21 Mar 2012 Planned end date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.